// App-Quantinova.ai

AB0905 (2018) : Long-term (5-YEAR efficacy and safety of apremilast monotherapy in dmard-naÏve subjects with active psoriatic arthritis

Researchers

Presenter

  • A.F. Wells

Principal Investigators

  • C.J. Edwards

  • A.J. Kivitz

  • P. Bird

  • B. Guerette

  • N. Delev

  • M. Paris

  • L. Teng

  • J.A. Aelion

Medical Centers

  • Rheumatology & Immunotherapy Center, Franklin, WI

  • University of Southampton, Southampton, UK

  • Altoona Center for Clinical Research, Duncansville, PA

  • Combined Rheumatology Practice, Kogarah, Australia

  • Celgene Corporation, Summit, NJ

  • West Tennessee Research Institute, Jackson, TN

Locations

  • United States

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Celgene Corporation

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved